Expression of Immune Checkpoint Regulators IDO, VISTA, LAG3, and TIM3 in Resected Pancreatic Ductal Adenocarcinoma
Pancreatic cancer features elaborate mechanisms of immune evasion. The potential of new immune molecules was explored to restore the antitumor immune response. If these immune molecules are associated with poor survival, specific drugs could take effect. Here, we analyze the expression of VISTA, LAG...
Main Authors: | Felix C. Popp, Ingracia Capino, Joana Bartels, Alexander Damanakis, Jiahui Li, Rabi R. Datta, Heike Löser, Yue Zhao, Alexander Quaas, Philipp Lohneis, Christiane J. Bruns, on behalf of the PANCALYZE Study Group |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-05-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/13/11/2689 |
Similar Items
-
Indoleamine 2,3-Dioxygenase (IDO) Downregulates the Cell Surface Expression of the CD4 Molecule
by: Lingfei Wu, et al.
Published: (2012-08-01) -
May critical molecular cross-talk between indoleamine 2,3-dioxygenase (IDO) and arginase during human aging be targets for immunosenescence control?
by: Ismael Dale Cotrim Guerreiro da Silva, et al.
Published: (2021-08-01) -
Indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors in clinical trials for cancer immunotherapy
by: Kai Tang, et al.
Published: (2021-04-01) -
Cancer immunotherapy by targeting IDO1/TDO and their downstream effectors
by: Michael ePlatten, et al.
Published: (2015-01-01) -
IDO Expression in Cancer: Different Compartment, Different Functionality?
by: Annabel Meireson, et al.
Published: (2020-09-01)